CHICAGO ( TheStreet) -- We get to see how cancer drug stocks fare in Monday trading following a weekend of data presentations at the American Society of Clinical Oncology (ASCO) annual meeting. Patrick Crutcher of Chimera Research Group and I are here for the next hour or so discussing the best and worst from the ASCO weekend to get ready for Monday's market open. Please join us and bring your questions and comments. The anti-PD-1 drugs from Bristol-Myers Squibb ( BMY) and Merck ( MRK) are generating the biggest buzz at this year's ASCO for the dramatic benefit observed in early-stage studies of advanced melanoma patients. Expectations for Bristol-Myers' nivolumab were high going into the conference but Merck may have stolen the show Sunday with lambrolizumab data that look as good or better. The weekend also brought incremental updates of the B-cell cancer drugs from Pharmacyclics ( PCYC) (ibrutinib), Gilead Sciences ( GILD) (idelalisib) and Infinity Pharmaceuticals ( INFI) (INF-145.) There was so much more happening this weekend at the ASCO annual meeting, so let's discuss. -- Reported by Adam Feuerstein in Chicago. Follow Adam Feuerstein on Twitter.